|
1
|
American Cancer Society: Cancer Facts
& Figures 2025. American Cancer Society; Atlanta: 2025
|
|
2
|
Kaufman MR, Eschliman EL and Karver TS:
Differentiating sex and gender in health research to achieve gender
equity. Bull World Health Organ. 101:666–671. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mauvais-Jarvis F, Bairey Merz N, Barnes
PJ, Brinton RD, Carrero JJ, DeMeo DL, De Vries GJ, Epperson CN,
Govindan R, Klein SL, et al: Sex and gender: Modifiers of health,
disease, and medicine. Lancet. 396:565–582. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delahousse J, Wagner AD, Borchmann S,
Adjei AA, Haanen J, Burgers F, Letsch A, Quaas A, Oertelt-Prigione
S, Özdemir BC, et al: Sex differences in the pharmacokinetics of
anticancer drugs: A systematic review. ESMO Open. 9:1040022024.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sosinsky AZ, Rich-Edwards JW, Wiley A,
Wright K, Spagnolo PA and Joffe H: Enrollment of female
participants in United States drug and device phase 1-3 clinical
trials between 2016 and 2019. Contemp Clin Trials. 115:1067182022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wagner AD, Oertelt-Prigione S, Adjei A,
Buclin T, Cristina V, Csajka C, Coukos G, Dafni U, Dotto GP,
Ducreux M, et al: Gender medicine and oncology: Report and
consensus of an ESMO workshop. Ann Oncol. 30:1914–1924. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim SE, Paik HY, Yoon H, Lee JE, Kim N and
Sung MK: Sex- and gender-specific disparities in colorectal cancer
risk. World J Gastroenterol. 21:5167–5175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdel-Rahman O: Impact of sex on
chemotherapy toxicity and efficacy among patients with metastatic
colorectal cancer: Pooled analysis of 5 randomized trials. Clin
Colorectal Cancer. 18:110–115 e2. 2019.PubMed/NCBI
|
|
9
|
Ferlay JEM, Lam F, Laversanne M, Colombet
M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F: Global
Cancer Observatory: Cancer Today. International Agency for Research
on Cancer; Lyon: Available from: https://gco.iarc.who.int/today2024.
|
|
10
|
Khalaf N, El-Serag HB, Abrams HR and
Thrift AP: Burden of pancreatic cancer: From epidemiology to
practice. Clin Gastroenterol Hepatol. 19:876–884. 2021. View Article : Google Scholar
|
|
11
|
Wang S, Zheng R, Li J, Zeng H, Li L, Chen
R, Sun K, Han B, Bray F, Wei W and He J: Global, regional, and
national lifetime risks of developing and dying from
gastrointestinal cancers in 185 countries: A population-based
systematic analysis of GLOBOCAN. Lancet Gastroenterol Hepatol.
9:229–237. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
GBD 2017 Pancreatic Cancer Collaborators:
The global, regional, and national burden of pancreatic cancer and
its attributable risk factors in 195 countries and territories,
1990-2017: A systematic analysis for the Global Burden of disease
study 2017. Lancet Gastroenterol Hepatol. 4:934–947. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cavazzani A, Angelini C, Gregori D and
Cardone L: Cancer incidence (2000-2020) among individuals under 35:
An emerging sex disparity in oncology. BMC Med. 22:3632024.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang J, Lok V, Ngai CH, Zhang L, Yuan J,
Lao XQ, Ng K, Chong C, Zheng ZJ and Wong MCS: Worldwide Burden of,
risk factors for, and trends in pancreatic cancer.
Gastroenterology. 160:744–754. 2021. View Article : Google Scholar
|
|
15
|
ECIS-European Cancer Information System.
2025, Available from: https://ecis.jrc.ec.europa.eu/explorer.php.
|
|
16
|
Lynch SM, Vrieling A, Lubin JH, Kraft P,
Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross
M, et al: Cigarette smoking and pancreatic cancer: A pooled
analysis from the pancreatic cancer cohort consortium. Am J
Epidemiol. 170:403–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gram IT, Park SY, Wilkens LR, Le Marchand
L and Setiawan VW: Smoking and pancreatic cancer: A sex-specific
analysis in the Multiethnic Cohort study. Cancer Causes Control.
34:89–100. 2023.
|
|
18
|
Bosetti C, Lucenteforte E, Silverman DT,
Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, et
al: Cigarette smoking and pancreatic cancer: An analysis from the
International pancreatic cancer case-control consortium (Panc4).
Ann Oncol. 23:1880–1888. 2012. View Article : Google Scholar :
|
|
19
|
Koyanagi YN, Ito H, Matsuo K, Sugawara Y,
Hidaka A, Sawada N, Wada K, Nagata C, Tamakoshi A, Lin Y, et al:
Smoking and pancreatic cancer incidence: A pooled analysis of 10
population-based cohort studies in Japan. Cancer Epidemiol
Biomarkers Prev. 28:1370–1378. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiao L, Berrington de Gonzalez A, Hartge
P, Pfeiffer RM, Park Y, Freedman DM, Gail MH, Alavanja MC, Albanes
D, Beane Freeman LE, et al: Body mass index, effect modifiers, and
risk of pancreatic cancer: A pooled study of seven prospective
cohorts. Cancer Causes Control. 21:1305–1314. 2010.PubMed/NCBI
|
|
21
|
Calle EE, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arslan AA, Helzlsouer KJ, Kooperberg C,
Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD,
Jacobs EJ, Lacroix AZ, et al: Anthropometric measures, body mass
index, and pancreatic cancer: A pooled analysis from the pancreatic
cancer cohort consortium (PanScan). Arch Intern Med. 170:791–802.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Johansen D, Stocks T, Jonsson H, Lindkvist
B, Bjorge T, Concin H, Almquist M, Häggström C, Engeland A, Ulmer
H, et al: Metabolic factors and the risk of pancreatic cancer: A
prospective analysis of almost 580,000 men and women in the
Metabolic Syndrome and cancer project. Cancer Epidemiol Biomarkers
Prev. 19:2307–2317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Genkinger JM, Kitahara CM, Bernstein L,
Berrington de Gonzalez A, Brotzman M, Elena JW, Giles GG, Hartge P,
Singh PN, Stolzenberg-Solomon RZ, et al: Central adiposity, obesity
during early adulthood, and pancreatic cancer mortality in a pooled
analysis of cohort studies. Ann Oncol. 26:2257–2266. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mao Y, Tao M, Jia X, Xu H, Chen K, Tang H
and Li D: Effect of diabetes mellitus on survival in patients with
pancreatic cancer: A systematic review and meta-analysis. Sci Rep.
5:171022015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mellenthin C, Balaban VD, Dugic A and
Cullati S: Risk factors for pancreatic cancer in patients with
new-onset diabetes: A systematic review and meta-analysis. Cancers
(Basel). 14:46842022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song S, Wang B, Zhang X, Hao L, Hu X, Li Z
and Sun S: Long-term diabetes mellitus is associated with an
increased risk of pancreatic cancer: A meta-analysis. PLoS One.
10:e01343212015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huxley R, Ansary-Moghaddam A, Berrington
de Gonzalez A, Barzi F and Woodward M: Type-II diabetes and
pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer.
92:2076–2083. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lucenteforte E, La Vecchia C, Silverman D,
Petersen GM, Bracci PM, Ji BT, Bosetti C, Li D, Gallinger S, Miller
AB, et al: Alcohol consumption and pancreatic cancer: A pooled
analysis in the International pancreatic cancer case-control
consortium (PanC4). Ann Oncol. 23:374–382. 2012. View Article : Google Scholar
|
|
30
|
Genkinger JM, Spiegelman D, Anderson KE,
Bergkvist L, Bernstein L, van den Brandt PA, English DR,
Freudenheim JL, Fuchs CS, Giles GG, et al: Alcohol intake and
pancreatic cancer risk: A pooled analysis of fourteen cohort
studies. Cancer Epidemiol Biomarkers Prev. 18:765–776. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiao L, Silverman DT, Schairer C, Thiebaut
AC, Hollenbeck AR, Leitzmann MF, Schatzkin A and
Stolzenberg-Solomon RZ: Alcohol use and risk of pancreatic cancer:
The NIH-AARP Diet and Health Study. Am J Epidemiol. 169:1043–1051.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arab JP, Dunn W, Im G and Singal AK:
Changing landscape of alcohol-associated liver disease in younger
individuals, women, and ethnic minorities. Liver Int. 44:1537–1547.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Santos R, Coleman HG, Cairnduff V and
Kunzmann AT: Clinical prediction models for pancreatic cancer in
general and at-risk populations: A systematic review. Am J
Gastroenterol. 118:26–40. 2023. View Article : Google Scholar
|
|
34
|
Gandhi S, de la Fuente J, Murad MH and
Majumder S: Chronic pancreatitis is a risk factor for pancreatic
cancer, and incidence increases with duration of disease: A
systematic review and meta-analysis. Clin Transl Gastroenterol.
13:e004632022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kirkegard J, Mortensen FV and
Cronin-Fenton D: Chronic pancreatitis and pancreatic cancer risk: A
systematic review and meta-analysis. Am J Gastroenterol.
112:1366–1372. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ilic M, Milicic B and Ilic I: Association
between oral contraceptive use and pancreatic cancer risk: A
systematic review and meta-analysis. World J Gastroenterol.
27:2643–2656. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Andersson G, Borgquist S and Jirstrom K:
Hormonal factors and pancreatic cancer risk in women: The Malmo
diet and cancer study. Int J Cancer. 143:52–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee E, Horn-Ross PL, Rull RP, Neuhausen
SL, Anton-Culver H, Ursin G, Henderson KD and Bernstein L:
Reproductive factors, exogenous hormones, and pancreatic cancer
risk in the CTS. Am J Epidemiol. 178:1403–1413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Prizment AE, Anderson KE, Hong CP and
Folsom AR: Pancreatic cancer incidence in relation to female
reproductive factors: Iowa women's health study. JOP. 8:16–27.
2007.PubMed/NCBI
|
|
40
|
Duell EJ and Holly EA: Reproductive and
menstrual risk factors for pancreatic cancer: A population-based
study of San Francisco Bay Area women. Am J Epidemiol. 161:741–747.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stevens RJ, Roddam AW, Green J, Pirie K,
Bull D, Reeves GK and Beral V; Million Women Study Collaborators:
Reproductive history and pancreatic cancer incidence and mortality
in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers
Prev. 18:1457–1460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ioannou C, Ragia G, Balgkouranidou I,
Xenidis N, Amarantidis K, Koukaki T, Biziota E, Kakolyris S and
Manolopoulos VG: MTHFR c.665C>T guided fluoropyrimidine therapy
in cancer: Gender-dependent effect on dose requirements. Drug Metab
Pers Ther. 37:323–327. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Conroy T, Pfeiffer P, Vilgrain V, Lamarca
A, Seufferlein T, O'Reilly EM, Hackert T, Golan T, Prager G,
Haustermans K, et al: Pancreatic cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up. Ann Oncol.
34:987–1002. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mueller F, Buchel B, Koberle D, Schurch S,
Pfister B, Krahenbuhl S, Froehlich TK, Largiader CR and Joerger M:
Gender-specific elimination of continuous-infusional 5-fluorouracil
in patients with gastrointestinal malignancies: Results from a
prospective population pharmacokinetic study. Cancer Chemother
Pharmacol. 71:361–370. 2013. View Article : Google Scholar
|
|
45
|
Milano G, Etienne MC, Cassuto-Viguier E,
Thyss A, Santini J, Frenay M, Renee N, Schneider M and Demard F:
Influence of sex and age on fluorouracil clearance. J Clin Oncol.
10:1171–1175. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bastian G, Barrail A and Urien S:
Population pharmacokinetics of oxaliplatin in patients with
metastatic cancer. Anticancer Drugs. 14:817–824. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nikanjam M, Stewart CF, Takimoto CH,
Synold TW, Beaty O, Fouladi M and Capparelli EV: Population
pharmacokinetic analysis of oxaliplatin in adults and children
identifies important covariates for dosing. Cancer Chemother
Pharmacol. 75:495–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Klein CE, Gupta E, Reid JM, Atherton PJ,
Sloan JA, Pitot HC, Ratain MJ and Kastrissios H: Population
pharmacokinetic model for irinotecan and two of its metabolites,
SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 72:638–647. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Berg AK, Buckner JC, Galanis E, Jaeckle
KA, Ames MM and Reid JM: Quantification of the impact of
enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics
and SN-38 exposure. J Clin Pharmacol. 55:1303–1312. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chabot GG, Abigerges D, Catimel G, Culine
S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R,
et al: Population pharmacokinetics and pharmacodynamics of
irinotecan (CPT-11) and active metabolite SN-38 during phase I
trials. Ann Oncol. 6:141–151. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
De Francia S, Mancardi D, Berchialla P,
Armando T, Storto S, Allegra S, Soave G, Racca S, Chiara F,
Carnovale J, et al: Gender-specific side effects of chemotherapy in
pancreatic cancer patients. Can J Physiol Pharmacol. 100:371–377.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim J, Ji E, Jung K, Jung IH, Park J, Lee
JC, Kim JW, Hwang JH and Kim J: Gender differences in patients with
metastatic pancreatic cancer who received FOLFIRINOX. J Pers Med.
11:832021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Keum J, Lee HS, Kang H, Jo JH, Chung MJ,
Park JY, Park SW, Song SY and Bang S: Single-center risk factor
analysis for FOLFIRINOX associated febrile neutropenia in patients
with pancreatic cancer. Cancer Chemother Pharmacol. 85:651–659.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sugiyama E, Kaniwa N, Kim SR, Hasegawa R,
Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, et al:
Population pharmacokinetics of gemcitabine and its metabolite in
Japanese cancer patients: Impact of genetic polymorphisms. Clin
Pharmacokinet. 49:549–558. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jiang X, Galettis P, Links M, Mitchell PL
and McLachlan AJ: Population pharmacokinetics of gemcitabine and
its metabolite in patients with cancer: Effect of oxaliplatin and
infusion rate. Br J Clin Pharmacol. 65:326–333. 2008. View Article : Google Scholar
|
|
56
|
Lim HS, Bae KS, Jung JA, Noh YH, Hwang AK,
Jo YW, Hong YS, Kim K, Lee JL, Park SJ, et al: Predicting the
efficacy of an oral paclitaxel formulation (DHP107) through
modeling and simulation. Clin Ther. 37:402–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Joerger M, Kraff S, Huitema AD, Feiss G,
Moritz B, Schellens JH, Beijnen JH and Jaehde U: Evaluation of a
pharmacology-driven dosing algorithm of 3-weekly paclitaxel using
therapeutic drug monitoring: A pharmacokinetic-pharmacodynamic
simulation study. Clin Pharmacokinet. 51:607–617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chen N, Li Y, Ye Y, Palmisano M, Chopra R
and Zhou S: Pharmacokinetics and pharmacodynamics of nab-paclitaxel
in patients with solid tumors: Disposition kinetics and
pharmacology distinct from solvent-based paclitaxel. J Clin
Pharmacol. 54:1097–1107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pijnappel EN, Schuurman M, Wagner AD, de
Vos-Geelen J, van der Geest LGM, de Groot JB, Koerkamp BG, de Hingh
IHJT, Homs MYV, Creemers GJ, et al: Sex, gender and age differences
in treatment allocation and survival of patients with metastatic
pancreatic cancer: A nationwide study. Front Oncol. 12:8397792022.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gehrels AM, Wagner AD, Besselink MG,
Verhoeven RHA, van Eijck CHJ, van Laarhoven HWM, Wilmink JW and van
der Geest LG; Dutch Pancreatic Cancer Group: Gender differences in
tumor characteristics, treatment allocation and survival in stage
I-III pancreatic cancer: A nationwide study. Eur J Cancer.
206:1141172024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Olsson Hau S, Williamsson C, Andersson B,
Eberhard J and Jirstrom K: Sex and gender differences in treatment
intention, quality of life and performance status in the first 100
patients with periampullary cancer enrolled in the CHAMP study. BMC
Cancer. 23:3342023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Williamsson C, Rystedt J and Andersson B:
An analysis of gender differences in treatment and outcome of
periampullary tumours in Sweden-A national cohort study. HPB
(Oxford). 23:847–853. 2021. View Article : Google Scholar
|
|
63
|
Pastrana Del Valle J, Mahvi DA,
Fairweather M, Wang J, Clancy TE, Ashley SW, Urman RD, Whang EE and
Gold JS: Associations of gender, race, and ethnicity with
disparities in short-term adverse outcomes after pancreatic
resection for cancer. J Surg Oncol. 125:646–657. 2022. View Article : Google Scholar
|
|
64
|
Lambert A, Jarlier M, Gourgou Bourgade S
and Conroy T: Response to FOLFIRINOX by gender in patients with
metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11
randomized trial. PLoS One. 12:e01832882017. View Article : Google Scholar
|
|
65
|
Hohla F, Hopfinger G, Romeder F,
Rinnerthaler G, Bezan A, Stattner S, Hauser-Kronberger C, Ulmer H
and Greil R: Female gender may predict response to FOLFIRINOX in
patients with unresectable pancreatic cancer: A single institution
retrospective review. Int J Oncol. 44:319–326. 2014. View Article : Google Scholar
|
|
66
|
Dunn SE, Perry WA and Klein SL: Mechanisms
and consequences of sex differences in immune responses. Nat Rev
Nephrol. 20:37–55. 2024. View Article : Google Scholar
|
|
67
|
Klein SL and Flanagan KL: Sex differences
in immune responses. Nat Rev Immunol. 16:626–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu
H and Han L: Sex-associated molecular differences for cancer
immunotherapy. Nat Commun. 11:17792020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Weinstein Y, Ran S and Segal S:
Sex-associated differences in the regulation of immune responses
controlled by the MHC of the mouse. J Immunol. 132:656–661. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Griesbeck M, Ziegler S, Laffont S, Smith
N, Chauveau L, Tomezsko P, Sharei A, Kourjian G, Porichis F, Hart
M, et al: Sex differences in plasmacytoid dendritic cell levels of
IRF5 drive higher IFN-α production in women. J Immunol.
195:5327–5336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Webb K, Peckham H, Radziszewska A, Menon
M, Oliveri P, Simpson F, Deakin CT, Lee S, Ciurtin C, Butler G, et
al: Sex and pubertal differences in the type 1 interferon pathway
associate with both X chromosome number and serum sex hormone
concentration. Front Immunol. 9:31672019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hagen SH, Henseling F, Hennesen J, Savel
H, Delahaye S, Richert L, Ziegler SM and Altfeld M: Heterogeneous
escape from x chromosome inactivation results in sex differences in
type I IFN responses at the single human pDC level. Cell Rep.
33:1084852020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Umlauf BJ, Haralambieva IH, Ovsyannikova
IG, Kennedy RB, Pankratz VS, Jacobson RM and Poland GA:
Associations between demographic variables and multiple
measles-specific innate and cell-mediated immune responses after
measles vaccination. Viral Immunol. 25:29–36. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Abramenko N, Vellieux F, Vesela K, Kejik
Z, Hajduch J, Masarik M, Babula P, Hoskovec D, Pacák K, Martásek P,
et al: Investigation of the potential effects of estrogen receptor
modulators on immune checkpoint molecules. Sci Rep. 14:30432024.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Han J, Yang Y, Li X, Wu J, Sheng Y, Qiu J,
Wang Q, Li J, He Y, Cheng L and Zhang Y: Pan-cancer analysis
reveals sex-specific signatures in the tumor microenvironment. Mol
Oncol. 16:2153–2173. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ho WJ, Jaffee EM and Zheng L: The tumour
microenvironment in pancreatic cancer-clinical challenges and
opportunities. Nat Rev Clin Oncol. 17:527–540. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Clark CE, Hingorani SR, Mick R, Combs C,
Tuveson DA and Vonderheide RH: Dynamics of the immune reaction to
pancreatic cancer from inception to invasion. Cancer Res.
67:9518–9527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
He F, Tay AHM, Calandigary A, Malki E,
Suzuki S, Liu T, Wang Q, Fernández-Moro C, Kaisso M, Olofsson-Sahl
P, et al: FPR2 shapes an immune-excluded pancreatic tumor
microenvironment and drives T-cell exhaustion in a sex-dependent
manner. Cancer Res. 83:1628–1645. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Manoukian P, van Schie DM, van Schelt AS,
Wassenaar NPM, Dings MPG, Lansbergen MF, Waasdorp C, Leite de
Oliveira R, Wickenhagen WV, Heijboer AC, et al: Estrogen production
in pancreatic cancer shapes a tumor suppressive stromal
microenvironment. Cancer Res. Nov 19–2025.Epub ahead of print.
PubMed/NCBI
|
|
81
|
Ahmed A, Kohler S, Klotz R, Giese N,
Hackert T, Springfeld C, Jäger D and Halama N: Sex differences in
the systemic and local immune response of pancreatic cancer
patients. Cancers (Basel). 15:18152023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
van Eijck CWF, Mustafa DAM, Vadgama D, de
Miranda NFCC, Groot Koerkamp B, van Tienhoven G, van der Burg SH,
Malats N and van Eijck CHJ; Dutch Pancreatic Cancer Group (DPCG):
Enhanced antitumour immunity following neoadjuvant
chemoradiotherapy mediates a favourable prognosis in women with
resected pancreatic cancer. Gut. 73:311–324. 2024. View Article : Google Scholar
|
|
83
|
Sethna Z, Guasp P, Reiche C, Milighetti M,
Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA, et
al: RNA neoantigen vaccines prime long-lived CD8(+) T cells in
pancreatic cancer. Nature. 639:1042–1051. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li Y, Chang RB, Stone ML, Delman D,
Markowitz K, Xue Y, Coho H, Herrera VM, Li JH, Zhang L, et al:
Multimodal immune phenotyping reveals microbial-T cell interactions
that shape pancreatic cancer. Cell Rep Med. 5:1013972024.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Andrews MC, Duong CPM, Gopalakrishnan V,
Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong
MC, et al: Gut microbiota signatures are associated with toxicity
to combined CTLA-4 and PD-1 blockade. Nat Med. 27:1432–1441. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Riquelme E, Zhang Y, Zhang L, Montiel M,
Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et
al: Tumor microbiome diversity and composition influence pancreatic
cancer outcomes. Cell. 178:795–806 e12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Guo W, Zhang Y, Guo S, Mei Z, Liao H, Dong
H, Wu K, Ye H, Zhang Y, Zhu Y, et al: Tumor microbiome contributes
to an aggressive phenotype in the basal-like subtype of pancreatic
cancer. Commun Biol. 4:10192021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Nejman D, Livyatan I, Fuks G, Gavert N,
Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E,
et al: The human tumor microbiome is composed of tumor
type-specific intracellular bacteria. Science. 368:973–980. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Guenther M, Gil L, Surendran SA, Palm MA,
Heinemann V, von Bergwelt-Baildon M, Mayerle J, Engel J, Werner J,
Boeck S and Ormanns S: Bacterial lipopolysaccharide as a negative
predictor of adjuvant gemcitabine efficacy in pancreatic cancer.
JNCI Cancer Spectr. 6:pkac0392022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Stein-Thoeringer CK, Renz BW, De Castilhos
J, von Ehrlich-Treuenstatt V, Wirth U, Tschaidse T, Hofmann FO,
Koch DT, Beirith I, Ormanns S, et al: Microbiome dysbiosis with
enterococcus presence in the upper gastrointestinal tract is a risk
factor for mortality in patients undergoing surgery for pancreatic
cancer. Ann Surg. 281:615–623. 2025. View Article : Google Scholar
|
|
91
|
Nalluri H, Jensen E and Staley C: Role of
biliary stent and neoadjuvant chemotherapy in the pancreatic tumor
microbiome. BMC Microbiol. 21:2802021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Khan ZA, Ghorbani M, Heffinger L,
Damdimopoulos A, Moro CF, Björnstedt M, Löhr JM, Heuchel R, Chen MS
and Sarhan D: Genderized gut and oral microbiome shifts: Uncovering
sex-specific dysbiosis in pancreatic cancer. bioRxiv. Oct
3–2024.Epub ahead of print. View Article : Google Scholar
|
|
93
|
Kaune T, Griesmann H, Theuerkorn K,
Hammerle M, Laumen H, Krug S, Plumeier I, Kahl S, Junca H, Gustavo
Dos Anjos Borges L, et al: Gender-specific changes of the gut
microbiome correlate with tumor development in murine models of
pancreatic cancer. iScience. 26:1068412023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Fulop DJ, Zylberberg HM, Wu YL, Aronson A,
Labiner AJ, Wisnivesky J, Cohen DJ, Sigel KM and Lucas AL:
Association of Antibiotic receipt with survival among patients with
metastatic pancreatic ductal adenocarcinoma receiving chemotherapy.
JAMA Netw Open. 6:e2342542023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
O'Neill RS and Stoita A: Biomarkers in the
diagnosis of pancreatic cancer: Are we closer to finding the golden
ticket? World J Gastroenterol. 27:4045–4087. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Balaban DV, Marin FS, Manucu G, Zoican A,
Ciochina M, Mina V, Patoni C, Vladut C, Bucurica S, Costache RS, et
al: Clinical characteristics and outcomes in carbohydrate antigen
19-9 negative pancreatic cancer. World J Clin Oncol. 13:630–640.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Hermann CD, Schoeps B, Eckfeld C,
Munkhbaatar E, Kniep L, Prokopchuk O, Wirges N, Steiger K, Häußler
D, Knolle P, et al: TIMP1 expression underlies sex disparity in
liver metastasis and survival in pancreatic cancer. J Exp Med.
218:e202109112021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Asplund E, Bergqvist M, Krook M and Lohr
JM: Plasma thymidine kinase activity as a prognostic biomarker in
pancreatic ductal adenocarcinoma: A single-center prospective
study. Scand J Gastroenterol. 58:1044–1048. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Babic A, Wang QL, Lee AA, Yuan C, Rifai N,
Luo J, Tabung FK, Shadyab AH, Wactawski-Wende J, Saquib N, et al:
Sex-specific associations between adiponectin and leptin signaling
and pancreatic cancer survival. Cancer Epidemiol Biomarkers Prev.
32:1458–1469. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao
F, Chen D, Wang Y, Hu J, Xia Q, et al: Characterization of the
genomic landscape in large-scale Chinese patients with pancreatic
cancer. EBioMedicine. 77:1038972022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Boeck S, Jung A, Laubender RP, Neumann J,
Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von
Weikersthal L, Clemens MR, et al: EGFR pathway biomarkers in
erlotinib-treated patients with advanced pancreatic cancer:
Translational results from the randomised, crossover phase 3 trial
AIO-PK0104. Br J Cancer. 108:469–476. 2013. View Article : Google Scholar :
|
|
102
|
Ramezankhani R, Ghavidel AA, Rashidi S,
Rojhannezhad M, Abolkheir HR, Mirhosseini M, Taleahmad S and
Vosough M: Gender-related differentially expressed genes in
pancreatic cancer: Possible culprits or accomplices? Front Genet.
13:9669412022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Peduzzi G, Archibugi L, Katzke V,
Gentiluomo M, Capurso G, Milanetto AC, Gazouli M, Goetz M, Brenner
H, Vermeulen RCH, et al: Common variability in oestrogen-related
genes and pancreatic ductal adenocarcinoma risk in women. Sci Rep.
12:181002022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Li D, Suzuki H, Liu B, Morris J, Liu J,
Okazaki T, Li Y, Chang P and Abbruzzese JL: DNA repair gene
polymorphisms and risk of pancreatic cancer. Clin Cancer Res.
15:740–746. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Jones J, Mukherjee A, Karanam B, Davis M,
Jaynes J, Reams RR, Dean-Colomb W and Yates C: African Americans
with pancreatic ductal adenocarcinoma exhibit gender differences in
Kaiso expression. Cancer Lett. 380:513–522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Schonk MM, Ducharme JB, Neyroud D, Nosacka
RL, Tucker HO, Judge SM and Judge AR: Myofiber-specific FoxP1
knockout protects against pancreatic cancer-induced muscle wasting
in male but not female mice. bioRxiv. Sep 21–2024.Epub ahead of
print. PubMed/NCBI
|
|
107
|
Zhong X, Narasimhan A, Silverman LM, Young
AR, Shahda S, Liu S, Wan J, Liu Y, Koniaris LG and Zimmers TA: Sex
specificity of pancreatic cancer cachexia phenotypes, mechanisms,
and treatment in mice and humans: Role of Activin. J Cachexia
Sarcopenia Muscle. 13:2146–2161. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Muckenhuber A, Berger AK, Schlitter AM,
Steiger K, Konukiewitz B, Trumpp A, Eils R, Werner J, Friess H,
Esposito I, et al: Pancreatic ductal adenocarcinoma subtyping using
the biomarkers hepatocyte nuclear Factor-1A and cytokeratin-81
correlates with outcome and treatment response. Clin Cancer Res.
24:351–359. 2018. View Article : Google Scholar
|
|
109
|
Guenther M, Surendran SA, Steinke LM, Liou
I, Palm MA, Heinemann V, Haas M, Boeck S and Ormanns S: The
prognostic, predictive and clinicopathological implications of
KRT81/HNF1A- and GATA6-Based transcriptional subtyping in
pancreatic cancer. Biomolecules. 15:4262025. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Nicolle R, Bachet JB, Harle A, Iovanna J,
Hammel P, Rebours V, Turpin A, Ben Abdelghani M, Wei A, Mitry E, et
al: Prediction of adjuvant gemcitabine sensitivity in resectable
pancreatic adenocarcinoma using the GemPred RNA signature: An
ancillary study of the PRODIGE-24/CCTG PA6 clinical trial. J Clin
Oncol. 42:1067–1076. 2024. View Article : Google Scholar :
|
|
111
|
Fraunhoffer N, Hammel P, Conroy T, Nicolle
R, Bachet JB, Harle A, Rebours V, Turpin A, Ben Abdelghani M, Mitry
E, et al: Development and validation of AI-assisted transcriptomic
signatures to personalize adjuvant chemotherapy in patients with
pancreatic ductal adenocarcinoma. Ann Oncol. 35:780–791. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Andricovich J, Perkail S, Kai Y, Casasanta
N, Peng W and Tzatsos A: Loss of KDM6A activates super-enhancers to
induce gender-specific squamous-like pancreatic cancer and confers
sensitivity to BET inhibitors. Cancer Cell. 33:512–526 e8. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Kouchi Y, Takano S, Harada-Kagitani S,
Shinomiya Y, Yogi N, Sakamoto T, Mishima T, Fugo K, Kambe M, Nagai
Y, et al: Complex glandular pattern is an aggressive morphology
that predicts poor prognosis of pancreatic ductal adenocarcinoma.
Ann Diagn Pathol. 64:1521102023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Grochowski P, Grosser B, Sommer F, Probst
A, Waidhauser J, Schenkirsch G, Reitsam NG and Märkl B: The concept
of stroma areactive invasion front areas (SARIFA) as a new
prognostic biomarker for lipid-driven cancers holds true in
pancreatic ductal adenocarcinoma. BMC Cancer. 24:7682024.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Hayashi A, Yavas A, McIntyre CA, Ho YJ,
Erakky A, Wong W, Varghese AM, Melchor JP, Overholtzer M, O'Reilly
EM, et al: Genetic and clinical correlates of entosis in pancreatic
ductal adenocarcinoma. Mod Pathol. 33:1822–1831. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Song J, Ruze R, Chen Y, Xu R, Yin X, Wang
C, Xu Q and Zhao Y: Construction of a novel model based on
cell-in-cell-related genes and validation of KRT7 as a biomarker
for predicting survival and immune microenvironment in pancreatic
cancer. BMC Cancer. 22:8942022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Xiong F, Guo T, Wang X, Wu G, Liu W, Wang
Q, Wang B and Chen Y: Keratin 8 is an inflammation-induced and
prognosis-related marker for pancreatic adenocarcinoma. Dis
Markers. 2022:81595372022. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Qian Y, Gong Y, Liu Y, Chen Y, Wang R, Dai
Z, Zou X, Tasiheng Y, Luo G, Lin X, et al: Atypical mucin
expression predicts worse overall survival in resectable pancreatic
ductal adenocarcinoma. J Immunol Res. 2022:73535722022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Ermiah E, Eddfair M, Abdulrahman O,
Elfagieh M, Jebriel A, Al-Sharif M, Assidi M and Buhmeida A:
Prognostic value of serum CEA and CA19-9 levels in pancreatic
ductal adenocarcinoma. Mol Clin Oncol. 17:1262022. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Sumiyoshi T, Uemura K, Shintakuya R, Okada
K, Baba K, Harada T, Serikawa M, Ishii Y, Nakamura S, Arihiro K, et
al: Clinical utility of the combined use of CA19-9 and DUPAN-2 in
pancreatic adenocarcinoma. Ann Surg Oncol. 31:4665–4672. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu
W, Liu J, Xiang J, Liang D, Hu Q, et al: Oncogenic KRAS targets
MUC16/CA125 in pancreatic ductal adenocarcinoma. Mol Cancer Res.
15:201–212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Xiao W, Hong H, Awadallah A, Zhou L and
Xin W: Utilization of CDX2 expression in diagnosing pancreatic
ductal adenocarcinoma and predicting prognosis. PLoS One.
9:e868532014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Amal AM, Ahmed MSM, Hareedy AAM, Khattab
HMH and Mahmoud EK: The utility of SMAD4 and S100P as diagnostic
immunohistochemical markers for pancreatic ductal adenocarcinomas
in egyptian patients. J Microsc Ultrastruct. Jun 25–2024.Epub ahead
of print. View Article : Google Scholar
|
